Analyst Price Targets — KYNB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 2, 2023 2:00 am | Annabel Samimy | Stifel Nicolaus | $28.00 | $17.32 | StreetInsider | Stifel Upgrades FibroGen (FGEN) to Buy |
Latest News for KYNB
Kyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026.
Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in 2H 2026 Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC, further validating key Phase 2 monotherapy design…
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KYNB.
U.S. House Trading
No House trades found for KYNB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.